Chi Hou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chi Hou has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Haixia Zhu
Guangzhou Medical University
3 shared publicationsKelu Zheng
Guangzhou Medical University
3 shared publicationsBingwei Peng
Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, The 9# Jin Sui Road, Guangzhou, Guangdong 510623, China
2 shared publicationsWenlin Wu
Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, The 9# Jin Sui Road, Guangzhou, Guangdong 510623, China
2 shared publications- Xiaojing Li
Department of Neurology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China
2 shared publications Yang Tian
Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, The 9# Jin Sui Road, Guangzhou, Guangdong 510623, China
2 shared publications
Latest Publications
- Open Access
- 8 April 2026
- Published by SAGE Publications in Journal of Central Nervous System Disease
- Vol. 18
Ofatumumab Treatment Used in Pediatric MOGAD: A Retrospective Case Series
Background: Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) is a rare central nervous system demyelinating disease with a variable course, including both monophasic and relapsing phenotypes. Effective treatment options, particularly for relapsing disease, remain limited. Ofatumumab (OFA), a subcutaneous anti-CD20 monoclonal antibody approved for multiple sclerosis, has not been studied in pediatric MOGAD. This study aims to assess its safety and efficacy in this population. Objective: To describe the safety and efficacy of off-label OFA use in pediatric MOGAD patients. Patients and Methods: We conducted a retrospective case series of consecutive pediatric patients with relapsing MOGAD who received OFA. Clinical data, including relapse history, annualized relapse rate (ARR), laboratory findings, and adverse events, were collected and analyzed. Results: Three pediatric (1 female, 2 males) were included. Age at onset was 2.3, 6.1, and 2.5 years; disease duration before OFA was 6.3, 2.2, and 9.1 years; and age at OFA initiation was 8.6, 8.3, and 11.6 years. Two patients started OFA due to breakthrough relapses on mycophenolate mofetil (MMF); one switched from maintenance intravenous immunoglobulin (IVIG) for administrative convenience. Treatment durations were 12, 9, and 9 months. All patients achieved rapid B-cell depletion (CD19+ < 10 cells/μL), which was sustained in two. Serum MOG-IgG titers increased in two patients and became negative in one. Two patients remained relapse-free during OFA treatment; one experienced a single relapse at 3 months. ARR decreased in all three patients post-OFA initiation. OFA was well tolerated. Only one patient developed transient fever after the first injection, which resolved with symptomatic treatment and did not recur. Conclusion: In this small case series, OFA was generally well-tolerated and associated with a reduction in ARR, suggesting a potential role in combination therapy for relapsing pediatric MOGAD. Given the use of combination treatments in some cases, including OFA+MMF and IVIG, the role of OFA alone remains unclear. Its subcutaneous route provides practical advantages in terms of convenience. Owing to the small sample size and relapse observed in one patient, these findings remain preliminary and warrant validation in larger, prospective studies.
- 8 April 2026
- Published by SAGE Publications in Journal of Central Nervous System Disease
- Vol. 18
Open AccessOfatumumab Treatment Used in Pediatric MOGAD: A Retrospective Case Series
Background: Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) is a rare central nervous system demyelinating disease with a variable course, including both monophasic and relapsing phenotypes. Effective treatment options, particularly for relapsing disease, remain limited. Ofatumumab (OFA), a subcutaneous anti-CD20 monoclonal antibody approved for multiple sclerosis, has not been studied in pediatric MOGAD. This study aims to assess its safety and efficacy in this population. Objective: To describe the safety and efficacy of off-label OFA use in pediatric MOGAD patients. Patients and Methods: We conducted a retrospective case series of consecutive pediatric patients with relapsing MOGAD who received OFA. Clinical data, including relapse history, annualized relapse rate (ARR), laboratory findings, and adverse events, were collected and analyzed. Results: Three pediatric (1 female, 2 males) were included. Age at onset was 2.3, 6.1, and 2.5 years; disease duration before OFA was 6.3, 2.2, and 9.1 years; and age at OFA initiation was 8.6, 8.3, and 11.6 years. Two patients started OFA due to breakthrough relapses on mycophenolate mofetil (MMF); one switched from maintenance intravenous immunoglobulin (IVIG) for administrative convenience. Treatment durations were 12, 9, and 9 months. All patients achieved rapid B-cell depletion (CD19+ < 10 cells/μL), which was sustained in two. Serum MOG-IgG titers increased in two patients and became negative in one. Two patients remained relapse-free during OFA treatment; one experienced a single relapse at 3 months. ARR decreased in all three patients post-OFA initiation. OFA was well tolerated. Only one patient developed transient fever after the first injection, which resolved with symptomatic treatment and did not recur. Conclusion: In this small case series, OFA was generally well-tolerated and associated with a reduction in ARR, suggesting a potential role in combination therapy for relapsing pediatric MOGAD. Given the use of combination treatments in some cases, including OFA+MMF and IVIG, the role of OFA alone remains unclear. Its subcutaneous route provides practical advantages in terms of convenience. Owing to the small sample size and relapse observed in one patient, these findings remain preliminary and warrant validation in larger, prospective studies.
- 1 July 2020
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 42, 102018
Clinical analysis of anti-NMDAR encephalitis combined with MOG antibody in children
- 1 July 2020
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 42, 102018
Clinical analysis of anti-NMDAR encephalitis combined with MOG antibody in children
- Open Access
- 12 November 2019
- Published by Springer Nature in Research Square
Clinical Analysis of Anti-NMDAR Encephalitis Combined with MOG Antibody in Children
Objective: To analyze the clinical features in children with anti-NMDAR encephalitis combined with myelin oligodendrocyte glycoprotein antibody (MOG ab).Methods: Clinical data of 7 children with anti-NMDAR encephalitis combined with MOG ab were collected in Guangzhou Women and Children’s Medical Center from January, 2016 to June, 2019.Results: Average onset age was 6.0±1.3 year-old, male to female was 2:5. Prominent symptoms in anti-NMDAR encephalitis were abnormal mental behavior (7/7), sleep disorder (6/7) and speech disorder (6/7), while in MOG ab related encephalomyelitis were encephalopathy (5/7) and paralysis (4/7). 1 case developed anti-NMDAR encephalitis 1 year after recovery from MOG ab related acute disseminated encephalomyelitis (ADEM). 4 cases developed anti-NMDAR encephalitis and MOG ab related ADEM simultaneously, with 2 cases relapsed. 2 cases were anti-NMDAR encephalitis with only MOG ab positive. 10 MRI examinations were performed in acute stage. 8/10 brain MRI showed abnormalities with multiple demyelinating lesions mainly involve subcortical white matter (7/8), cortex (6/8) and basal ganglia (5/8). 2/10 had long segment myelitis. Patients improved significantly after corticosteroid and intravenous immunoglobulin (IVIG) treatment. Patients with recurrent course (n=2) had higher MOG ab titer (1:320) and longer duration (≥12 months) compared with non-recurrent course (n=5), MOG antibody(≤1:100) (≤6 months). 3 Cases had neurological sequelae with higher cerebrospinal fluid (CSF) NMDAR antibody titer at first onset (1:320). 2 had emotional problems and 1 had epilepsy.Conclusion: Children with anti-NMDAR encephalitis combined with MOG ab were more common in girls around 6 year-old. Patients responded well to Corticosteroid and IVIG. Cases with persistent MOG ab need longer follow-up due to recurrent risk, high titer of CSF NMDAR antibody may cause neurological sequelae. Keywords: anti-NMDAR encephalitis, myelin oligodendrocyte glycoprotein antibody, children
- 12 November 2019
- Published by Springer Nature in Research Square
Open AccessClinical Analysis of Anti-NMDAR Encephalitis Combined with MOG Antibody in Children
Objective: To analyze the clinical features in children with anti-NMDAR encephalitis combined with myelin oligodendrocyte glycoprotein antibody (MOG ab).Methods: Clinical data of 7 children with anti-NMDAR encephalitis combined with MOG ab were collected in Guangzhou Women and Children’s Medical Center from January, 2016 to June, 2019.Results: Average onset age was 6.0±1.3 year-old, male to female was 2:5. Prominent symptoms in anti-NMDAR encephalitis were abnormal mental behavior (7/7), sleep disorder (6/7) and speech disorder (6/7), while in MOG ab related encephalomyelitis were encephalopathy (5/7) and paralysis (4/7). 1 case developed anti-NMDAR encephalitis 1 year after recovery from MOG ab related acute disseminated encephalomyelitis (ADEM). 4 cases developed anti-NMDAR encephalitis and MOG ab related ADEM simultaneously, with 2 cases relapsed. 2 cases were anti-NMDAR encephalitis with only MOG ab positive. 10 MRI examinations were performed in acute stage. 8/10 brain MRI showed abnormalities with multiple demyelinating lesions mainly involve subcortical white matter (7/8), cortex (6/8) and basal ganglia (5/8). 2/10 had long segment myelitis. Patients improved significantly after corticosteroid and intravenous immunoglobulin (IVIG) treatment. Patients with recurrent course (n=2) had higher MOG ab titer (1:320) and longer duration (≥12 months) compared with non-recurrent course (n=5), MOG antibody(≤1:100) (≤6 months). 3 Cases had neurological sequelae with higher cerebrospinal fluid (CSF) NMDAR antibody titer at first onset (1:320). 2 had emotional problems and 1 had epilepsy.Conclusion: Children with anti-NMDAR encephalitis combined with MOG ab were more common in girls around 6 year-old. Patients responded well to Corticosteroid and IVIG. Cases with persistent MOG ab need longer follow-up due to recurrent risk, high titer of CSF NMDAR antibody may cause neurological sequelae. Keywords: anti-NMDAR encephalitis, myelin oligodendrocyte glycoprotein antibody, children